Literature DB >> 29378711

Population Pharmacokinetics of Cefotaxime and Dosage Recommendations in Children with Sickle Cell Disease.

Elsa Maksoud1, Berengere Koehl2,3, Aude Facchin1, Phuong Ha1, Wei Zhao1, Florentia Kaguelidou1,4,5, Malika Benkerrou2, Patricia Mariani6, Albert Faye3,5, Mathie Lorrot3,5, Evelyne Jacqz-Aigrain7,4,5.   

Abstract

The pharmacokinetic profile of most drugs is dependent on the patient's covariates and may be influenced by the disease. Cefotaxime is frequently prescribed in pediatric patients with sickle cell disease (SCD), characterized by vaso-occlusive complications, chronic hemolytic anemia, and a defective immunological function predisposing the individual to severe infection. Data on the impact of the disease on the disposition of cefotaxime are missing. In the present study, our aims were to determine cefotaxime pharmacokinetics when prescribed to children with SCD for suspected or proven bacterial infection, identify significant covariates, and perform Monte Carlo simulations to optimize the drug dosage. Cefotaxime serum concentrations were measured in 78 pediatric SCD patients receiving cefotaxime intravenously at a daily dose of 200 mg/kg of body weight in three or four divided doses over 30 min. A total of 107 concentrations were available for pharmacokinetic analysis. A population pharmacokinetic model was developed with NONMEM software and used for Monte Carlo simulations. Cefotaxime concentrations ranged from 0.05 to 103.7 mg/liter. Cefotaxime pharmacokinetics were best described by a one-compartment model: the median estimated weight-normalized volume of distribution and clearance were 0.42 liter/kg (range, 0.2 to 1.1 liter/kg) and 0.38 liter/h/kg (range, 0.1 to 1.2 liter/h/kg). Cefotaxime clearance increased by 22% in patients with acute chest syndrome. Dosing optimization, performed using EUCAST MIC susceptibility breakpoints, showed that a dose of 100 mg/kg/6 h should be used, depending on the patient's characteristics and clinical presentation, in order to reach a value of the percentage of time that the drug concentration exceeded the MIC under steady-state pharmacokinetic conditions of 80% in 80% of the patients when targeting sensitive Gram-positive cocci and Gram-negative bacilli with MICs of 1 mg/liter or below.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Monte Carlo simulation; cefotaxime; dosage adaptation; pediatrics; population pharmacokinetics; sickle cell disease

Mesh:

Substances:

Year:  2018        PMID: 29378711      PMCID: PMC5914001          DOI: 10.1128/AAC.00637-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  35 in total

Review 1.  Susceptibility to invasive bacterial infections in children with sickle cell disease.

Authors:  Anna J Battersby; Huxley H M Knox-Macaulay; Enitan D Carrol
Journal:  Pediatr Blood Cancer       Date:  2010-09       Impact factor: 3.167

Review 2.  Infection in sickle cell disease: a review.

Authors:  Catherine Booth; Baba Inusa; Stephen K Obaro
Journal:  Int J Infect Dis       Date:  2009-06-03       Impact factor: 3.623

3.  Salmonella infection in sickle cell disease: a clear and present danger.

Authors:  R E Ware
Journal:  J Pediatr       Date:  1997-03       Impact factor: 4.406

Review 4.  The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation.

Authors:  M G Cherry; J Greenhalgh; L Osipenko; M Venkatachalam; A Boland; Y Dundar; K Marsh; R Dickson; D C Rees
Journal:  Health Technol Assess       Date:  2012       Impact factor: 4.014

Review 5.  Penetration of newer cephalosporins into cerebrospinal fluid.

Authors:  C E Cherubin; R H Eng; R Norrby; J Modai; G Humbert; G Overturf
Journal:  Rev Infect Dis       Date:  1989 Jul-Aug

Review 6.  Third generation cephalosporins: safety profiles after 10 years of clinical use.

Authors:  H C Neu
Journal:  J Clin Pharmacol       Date:  1990-05       Impact factor: 3.126

7.  Predictors of bacteremia in febrile children with sickle cell disease.

Authors:  Daniel C West; Emily Andrada; Rahman Azari; Arun A Rangaswami; Nathan Kuppermann
Journal:  J Pediatr Hematol Oncol       Date:  2002-05       Impact factor: 1.289

8.  Hepatic function as assessed by lidocaine metabolism in sickle cell disease.

Authors:  D A Gremse; E Fillingim; C J Hoff; D J Wells; R C Boerth
Journal:  J Pediatr       Date:  1998-06       Impact factor: 4.406

9.  Antimicrobial activity of desacetylcefotaxime alone and in combination with cefotaxime: evidence of synergy.

Authors:  R N Jones; A L Barry; C Thornsberry
Journal:  Rev Infect Dis       Date:  1982 Sep-Oct

10.  Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination.

Authors:  Thomas V Adamkiewicz; Sharada Sarnaik; George R Buchanan; Rathi V Iyer; Scott T Miller; Charles H Pegelow; Zora R Rogers; Elliott Vichinsky; John Elliott; Richard R Facklam; Katherine L O'Brien; Benjamin Schwartz; Chris A Van Beneden; Michael J Cannon; James R Eckman; Harry Keyserling; Kevin Sullivan; Wing-Yen Wong; Winfred C Wang
Journal:  J Pediatr       Date:  2003-10       Impact factor: 4.406

View more
  6 in total

1.  Population Pharmacokinetic Estimates Suggest Elevated Clearance and Distribution Volume of Desethylamodiaquine in Pediatric Patients with Sickle Cell Disease Treated with Artesunate-Amodiaquine.

Authors:  George O Adjei; Seth K Amponsah; Bamenla Q Goka; Christabel Enweronu-Laryea; Lorna Renner; Abdul Malik Sulley; Michael Alifrangis; Jorgen A L Kurtzhals
Journal:  Curr Ther Res Clin Exp       Date:  2019-01-12

2.  Population pharmacokinetics of cefotaxime in intensive care patients.

Authors:  Maria Swartling; Anna-Karin Smekal; Mia Furebring; Miklos Lipcsey; Siv Jönsson; Elisabet I Nielsen
Journal:  Eur J Clin Pharmacol       Date:  2021-10-01       Impact factor: 2.953

3.  Population pharmacokinetics of intravenous cefotaxime indicates that higher doses are required for critically ill children.

Authors:  Stan J F Hartman; Parth J Upadhyay; Ron A A Mathôt; Michiel van der Flier; Michiel F Schreuder; Roger J Brüggemann; Catherijne A Knibbe; Saskia N de Wildt
Journal:  J Antimicrob Chemother       Date:  2022-05-29       Impact factor: 5.758

4.  Optimal dose of cefotaxime in neonates with early-onset sepsis: A developmental pharmacokinetic model-based evaluation.

Authors:  Zhen-Hai Shang; Yue-E Wu; Dong-Mei Lv; Wei Zhang; Wen-Qiang Liu; John van den Anker; Yan Xu; Wei Zhao
Journal:  Front Pharmacol       Date:  2022-09-07       Impact factor: 5.988

5.  THE EXPOSOME IN HUMAN EVOLUTION: FROM DUST TO DIESEL.

Authors:  Benjamin C Trumble; Caleb E Finch
Journal:  Q Rev Biol       Date:  2019-12       Impact factor: 6.750

6.  Pharmacokinetics Alterations in Critically Ill Pediatric Patients on Extracorporeal Membrane Oxygenation: A Systematic Review.

Authors:  Natalia Sutiman; Janine Cynthia Koh; Kevin Watt; Christoph Hornik; Beverly Murphy; Yoke Hwee Chan; Jan Hau Lee
Journal:  Front Pediatr       Date:  2020-06-26       Impact factor: 3.418

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.